Despite the early success of PARP inhibitors in demonstrating efficacy and a favorable toxicity profile in the treatment of previously heavily treated hereditary BRCA1/2-related breast and ovarian cancers [19-22], trials that expanded to include patients without BRCA1/2 mutations were less successful. This evidence concerns the gene PARP1 and ovarian cancer.